The evidence supports an association between the endonasal approach and better resection and visual outcomes in this selected cohort; it may therefore improve anatomy-guided surgical outcomes for appropriately located craniopharyngiomas, but this remains an inference because nonrandom approach allocation and baseline anatomical differences preclude a causal comparison.

The supplied evidence supports HDAC8 as a pharmacologically addressable dependency in STAG2-mutant Ewing sarcoma; it remains an inference, requiring in vivo and clinical validation, that HDAC8 degradation could selectively treat this high-risk subtype.

Evidence in the supplied record supports early, genotype-matched CFTR modulation as an effective cystic-fibrosis treatment strategy; it can only be inferred—not concluded—that longer survival, future malignancy risk, and interactions between modulators and anticancer drugs may become relevant to pediatric-oncology care.

The supplied record supports chemotherapy-related CNS injury as an important survivorship and quality-of-life problem; it further proposes—but does not demonstrate—that prevention, monitoring, and supportive interventions tailored to treatment phase and chemotherapy regimen could improve CNS protection.

The supplied evidence supports AESS as a candidate skin-barrier intervention in atopic dermatitis and links its effects to keratinocyte autophagy and Hippo-YAP signaling; any relevance to pediatric cancer, cancer-associated dermatitis, or oncology treatment toxicity is purely inferential and was not tested.

The observed short-term remissions provide evidence that favorable outcomes are achievable for some children with Wilms’ tumor in this resource-limited setting; it is only an inference that improving access to standardized multimodal therapy and longer surveillance would further improve outcomes, and the study does not establish that limited chemotherapy or omission of radiotherapy is safe or effective.

The evidence shows frequent malignancy-first presentation, advanced disease, prognostic associations, and no observed post-transplant relapse in a small selected HSCT subgroup; it supports the inference—not proof—that earlier immunologic evaluation and risk-adapted consideration of HSCT could improve management for some children with IEI-associated cancer.

The supplied evidence supports a subgroup-specific association based on predicted drug sensitivity, not demonstrated treatment efficacy; it suggests the testable hypothesis that ODC1 expression may help identify MYCN non-amplified neuroblastomas more likely to respond to DFMO.

The evidence shows that hilar-to-central vessel distance correlates with selection for laparoscopic rather than open nephrectomy; it remains an inference, requiring prospective multicenter validation, that adding this measurement to established clinical and imaging criteria could improve surgical selection and reduce operative risk.

The evidence supports investigation of pretreatment cytokines as risk-stratification biomarkers in pediatric PMBCL; it is only an inference, not tested here, that IL-6 or related cytokine signaling could identify actionable biology or guide treatment intensification or targeted intervention.

The record supports AKI as a potential marker of later kidney impairment and identifies inadequate creatinine monitoring as a detection gap; it is reasonable—but untested here—to hypothesize that systematic renal surveillance and targeted preventive measures during and after CNS tumor therapy could reduce or enable earlier management of kidney toxicity.

The reported cases provide preliminary evidence that adding anti-GD2 therapy early during induction may be feasible and tolerable; it is an inference—not established by this uncontrolled two-patient report—that earlier naxitamab could improve response or outcomes compared with standard sequencing.